The WFH Global Forum is an essential event for anyone with an interest in the developments that are shaping the global bleeding disorders community today. With several new therapeutic options available—and more in the pipeline—it’s time to collectively assess these advances, identify their strengths and limitations, determine what will facilitate or hinder their adoption, and evaluate their impact on patients.
This year, gene therapy has been fully integrated into the event. It will be included as part of discussions on the overall treatment landscape, and as a unique therapeutic option on its own. This brings the WFH Global Forum to a new level, and it means that you will have a unique opportunity to gain a truly global perspective on the cutting-edge developments taking place in our field today.
Here’s a quick peek at the Program for November’s event:
- Two full sessions will cover approaches to confronting the current limitations of replacement, non-replacement, and gene therapies
- Hot Topics, including recently-approved—and still in the pipeline—non-factor products: nxt007, mim8, concizumab, fitusiran, and more!
- Therapeutic options for people with moderate and mild hemophilia, women and girls with bleeding disorders, and rare bleeding disorders
- Inequities in healthcare delivery
- Innovative access programs
- “Learning from the past, and preparing for the future”, a keynote talk by award winning health and public policy journalist, André Picard
By attending the 13th WFH Global Forum, you will also have the chance to win a free registration to the WFH 2024 World Congress in Madrid, which will be the most comprehensive international event on bleeding disorders in 2024.
Visit our website to learn more about the program, key speakers, and registration details. Click here to register now and secure your spot for the 13th WFH Global Forum.
The 13th edition of the WFH Global Forum is supported by funding from BioMarin, CSL Behring, Sobi and Spark Therapeutics.